2-(3,4-dihydro-1H-2-benzopyran-1-yl)acetic acid → (+)-1-[2-(Isochroman-1-yl)ethyl]-4-(4-methoxyphenyl)piperazine dihydrochloride

HRID 368858

Reaktionsgleichung

Reaktionsgleichung von HRID 368858
[CH:1]1(CC(O)=O)C2C(=CC=CC=2)CC[O:2]1.[OH2:15].[ClH:16].Cl.[CH:18]1([CH2:28][CH2:29][N:30]2[CH2:35][CH2:34][N:33]([C:36]3[CH:41]=[CH:40][CH:39]=[CH:38][C:37]=3OC)[CH2:32][CH2:31]2)[C:27]2[C:22](=[CH:23][CH:24]=[CH:25][CH:26]=2)[CH2:21][CH2:20]O1>>[ClH:16].[ClH:16].[CH:18]1([CH2:28][CH2:29][N:30]2[CH2:31][CH2:32][N:33]([C:36]3[CH:41]=[CH:40][C:39]([O:2][CH3:1])=[CH:38][CH:37]=3)[CH2:34][CH2:35]2)[C:27]2[C:22](=[CH:23][CH:24]=[CH:25][CH:26]=2)[CH2:21][CH2:20][O:15]1

Komponenten

3

Edukt 2

HCID 133088642-(3,4-dihydro-1H-2-benzopyran-1-yl)acetic acid3×HCID 232889511-[2-(Isochroman-1-yl)ethyl]-4-(2-methoxyphenyl)piperazine dihydrochloride monohydrate

Produkt 1

HCID 23288856(+)-1-[2-(Isochroman-1-yl)ethyl]-4-(4-methoxyphenyl)piperazine dihydrochloride

Versuchsvorschrift

Following the general procedure of EXAMPLE 48 and making non-critical variations but using (+)-(isochroman-1-yl)acetic acid (prepared in the same manner as for EXAMPLE 45, Step 3, but using S-(-)-α-methylbenzylamine in place of R-(+)-α-methylbenzylamine), containing some (-)-(isochroman-1-yl)acetic acid as an impurity, in place of (-)-(isochroman-1-yl)acetic acid (LXI, EXAMPLE 45--Step 3), and using 1-(4-methoxyphenyl)piperazine dihydrochloride (XI) in place of 4-(piperazin-1-yl)benzamide (IV), the title compound is obtained, mp 210-216°; [α]+42 (c 0.99, CH2Cl2).

Aufarbeitung

  1. customprepared in the same manner as for EXAMPLE 45, Step 3

Quellen und Nachweise

ORD-Eintrag
ord-ee950aa8cd0c40318e5384e1c41fc09a
Quelldatensatz
uspto-grants-2000_10
Patentnummer
US06133446

Verknüpfte Notizen

Wird geladen…